CION Ameerpet
Invasive ductal carcinoma (IDC) is the commonest type of breast cancer, making up around 70–80% of all invasive breast cancers. It begins in a milk duct and has broken through the duct wall into the surrounding breast tissue — which is what makes it "invasive", unlike DCIS (ductal carcinoma in situ), where the cells are still contained inside the duct. IDC is very treatable, and the right plan depends on its grade, stage and hormone/HER2 status. At CION, a woman-headed, tumour-board-led team confirms the diagnosis accurately and builds a clear plan — without rushed decisions or unnecessary tests.
Invasive ductal carcinoma (IDC) is the most common type of breast cancer, accounting for roughly 70–80% of all invasive breast cancers. "Ductal" means it begins in the lining of a milk duct; "invasive" means the cancer cells have broken through the wall of that duct and grown into the surrounding breast tissue. Because most IDCs do not have a special distinguishing pattern under the microscope, pathologists also call it invasive carcinoma of "no special type" (NST) or "not otherwise specified (NOS)".
The word "invasive" is the key difference from DCIS (ductal carcinoma in situ), where the abnormal cells are still trapped inside the duct and have not spread — a non-invasive, "stage 0" condition. IDC is confirmed on a breast biopsy, and once invasion is confirmed the same report guides every later decision through receptor testing, grade and stage.
About 70–80% of invasive breast cancers are IDC. It is so common that "breast cancer" in everyday speech usually means invasive ductal carcinoma.
IDC has grown beyond the duct wall into surrounding tissue. That makes it different from DCIS, which stays inside the duct and is treated as stage 0.
A biopsy confirms IDC; ER, PR and HER2 testing then sorts it into a subtype that decides which systemic treatment will work.
Invasive ductal carcinoma is by far the commonest breast cancer — about 70–80% of all invasive cases. The next most common type, invasive lobular carcinoma, makes up roughly 10–15%. The big practical difference is what the pathologist looks for: IDC usually forms a distinct lump that shows up clearly on a mammogram, while lobular cancer tends to spread in single-file lines and can be harder to see. That is why accurate biopsy and imaging matter for every breast lump. Source: WHO / NCCN Breast Cancer guidance; SEER.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Breast cancer reports use words that sound similar but mean very different things. The most important distinction is between "in situ" (still inside the duct, non-invasive) and "invasive" (has spread into surrounding tissue). Getting this right matters, because DCIS and IDC are treated very differently even though both start in a duct.
The second distinction is between the two main invasive types — ductal and lobular — which behave and show up differently. Here is how they compare.
Cancer cells are present but still contained inside the milk duct — they have not invaded. It is non-invasive, often called "stage 0", and cannot spread to other organs while it stays in situ. Read more about DCIS.
The same ductal origin, but the cells have broken through the duct wall into surrounding breast tissue. This is what "invasive" means, and it is why IDC needs staging and, often, systemic treatment as well as surgery.
The second commonest invasive type starts in the milk-producing lobules and tends to spread in single-file lines rather than forming one firm lump — so it can be harder to feel and to see on a mammogram. Learn about ILC.
Unlike lobular cancer, IDC commonly forms a single, firm mass that is felt as a lump or seen as a clear density on a mammogram — which is one reason it is the most frequently detected breast cancer.
Every IDC is given a grade of 1, 2 or 3. Grade is not the same as stage: stage describes how far the cancer has spread, while grade describes how abnormal the cells look under the microscope and how quickly they appear to be dividing. The pathologist scores three features — how well the cancer forms duct-like tubules, how irregular the cell nuclei look, and how often the cells are dividing — and adds them up to give the grade.
In general, a lower grade tends to grow more slowly and a higher grade more quickly. Grade is one of several factors — alongside size, node status and receptor subtype — that the team weighs when deciding whether systemic treatment is needed.
The cancer cells still look fairly similar to normal breast cells and form recognisable duct-like structures. These are described as well-differentiated and usually tend to grow more slowly.
The cells look moderately abnormal — somewhere between grade 1 and grade 3. This moderately-differentiated grade is the most common result for IDC.
The cells look very abnormal (poorly differentiated) and are dividing more rapidly. Higher-grade IDC is often treated more intensively, though it can also be more responsive to chemotherapy.
Grade helps decide whether chemotherapy is likely to add benefit, and it feeds into prognosis estimates alongside stage and ER/PR/HER2 status — which is why your report lists all of them together.
Invasive ductal carcinoma usually announces itself as a new breast lump, because it tends to form a distinct firm mass. But it can also show up as subtler skin or nipple changes, and some early IDCs are picked up on screening before anything can be felt. Most breast changes are not cancer — but the ones that are need to be found early, so any change that persists deserves a check.
The classic sign of IDC — often firm, sometimes painless, and frequently with an irregular edge. A lump that does not come and go with your period should always be reviewed.
Swelling of part of the breast, or a new difference between the two breasts that was not there before.
Skin that puckers or dimples as the tumour pulls on the tissue, thickening, or redness over part of the breast.
A newly pulled-in (inverted or retracted) nipple, or nipple discharge other than breast milk — especially if it is bloody or from one duct.
Some IDCs are detected on a screening mammogram as a small mass or calcifications, before any lump can be felt — which is why regular screening matters.
Because IDC is the commonest breast cancer, it is also the one where small differences in planning add up — the right surgery, the right systemic treatment for your receptor subtype, and the right order. CION is a woman-headed, tumour-board-led organisation built for these decisions, so your plan is chosen by a full panel rather than one person.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumor-board-reviewed care for invasive ductal carcinoma across 35+ centres in Telangana & AP. Call 1800-202-8726.
The journey from a breast change to an IDC diagnosis follows a clear order: a clinical examination, then imaging, then a biopsy that confirms the cancer and whether it has invaded. Only a biopsy can prove the diagnosis — imaging alone can raise suspicion but cannot tell invasive cancer apart from a harmless change with certainty.
Once IDC is confirmed, the same tissue sample is tested for the hormone receptors and HER2. This receptor result is what divides IDC into its subtypes — and it is the single most important factor in deciding which systemic treatment will help.
"Invasive ductal carcinoma" describes where the cancer started and that it has invaded — but it does not, on its own, tell the oncologist how to treat it. That comes from the receptor result. The same IDC can be hormone-receptor-positive, HER2-positive, or triple-negative, and these subtypes are treated very differently. This is why two women who both have "invasive ductal carcinoma" can end up on completely different treatments.
At CION the subtype is confirmed before any systemic treatment is planned, so the right drugs are matched to your specific biology.
Once IDC is confirmed, the team works out the stage — based on the size of the tumour, whether it has reached the lymph nodes, and whether it has spread to other organs. Treatment then combines local treatment (surgery, and usually radiation) with systemic treatment chosen by the receptor subtype. For most early IDC, surgery is either a breast-conserving lumpectomy or a mastectomy, with a sentinel lymph node biopsy to check the nodes.
Systemic treatment is matched to the subtype: hormone therapy for hormone-positive IDC, HER2-targeted therapy for HER2-positive IDC, and chemotherapy where it adds benefit. Prognosis depends on stage, grade and subtype together. Early invasive ductal carcinoma is often treated with the goal of cure, and a large proportion of women are cured; advanced (metastatic) IDC is generally not curable but is treatable, with treatment that can control it and extend good-quality life. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
An IDC pathology report can look like a wall of unfamiliar terms, but each line is there for a reason — and together they decide your treatment. Knowing what the main parts mean helps you ask better questions and feel more in control of your care. Here are the items that matter most on a typical invasive ductal carcinoma report.
At CION your specialist goes through the report with you in plain language, so you understand what each result means before any treatment is planned.
An invasive ductal carcinoma diagnosis raises a lot of questions at once. You do not have to navigate them alone. CION offers a clear, woman-led pathway from first consultation to treatment, built around your grade, stage and receptor subtype — with your first consultation free.
A specialist reviews your biopsy and reports in full, explains what "invasive ductal carcinoma" means for you, and outlines the likely plan — no rushed decisions, no unnecessary tests.
We make sure invasion is confirmed and the ER/PR/HER2 status, grade and Ki67 are accurate — arranging any further imaging or testing needed, with up to 50% discounts on diagnostics.
3+ oncologists plan your care together — surgery (lumpectomy or mastectomy) with a sentinel node biopsy, radiation, and the systemic therapy matched to your subtype.
Surgery, radiation, hormone therapy, HER2-targeted therapy or chemotherapy as needed — with nutrition, psycho-oncology and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Invasive ductal carcinoma (IDC) is the commonest type of breast cancer — about 70–80% of all invasive cases. "Ductal" means it starts in the lining of a milk duct, and "invasive" means the cancer cells have broken through the duct wall into the surrounding breast tissue. Because most IDCs have no special pattern under the microscope, it is also called invasive carcinoma of "no special type" (NST) or "not otherwise specified" (NOS) — these are simply other names for the same diagnosis. IDC is confirmed on a breast biopsy, after which the tissue is tested for hormone receptors and HER2 to decide treatment.
Both start in a milk duct, but the crucial difference is invasion. In DCIS (ductal carcinoma in situ), the abnormal cells are still trapped inside the duct and have not spread — it is non-invasive and is often called "stage 0". In invasive ductal carcinoma the cells have broken through the duct wall into the surrounding breast tissue, which means it can potentially spread to lymph nodes or beyond and needs staging. Because of this, DCIS and IDC are treated differently: DCIS is usually managed with surgery and sometimes radiation, while IDC may also need systemic treatment such as hormone therapy, HER2-targeted therapy or chemotherapy depending on its subtype.
They are the two commonest invasive breast cancers, but they start in different places and behave differently. IDC begins in a milk duct and usually forms a single, distinct firm lump that shows up clearly on a mammogram — it makes up about 70–80% of invasive breast cancers. Invasive lobular carcinoma starts in the milk-producing lobules and tends to spread in single-file lines rather than forming one clear mass, so it can be harder to feel and to see on imaging, and is sometimes found in more than one area. The treatment principles are similar — both are guided by grade, stage and receptor status — but the differences matter for diagnosis and surgical planning.
Diagnosis follows a clear order. It usually starts with a clinical breast examination, then imaging — a mammogram and often an ultrasound. If something suspicious is seen, a core needle biopsy removes small samples of tissue so a pathologist can confirm whether cancer cells have invaded beyond the duct wall, which is what defines IDC. The same biopsy is then tested for the oestrogen receptor (ER), progesterone receptor (PR) and HER2, and given a grade. Only a biopsy can confirm the diagnosis — imaging alone can raise suspicion but cannot prove invasive cancer. This complete report is what the tumour board uses to plan treatment.
Grade describes how abnormal the cancer cells look under the microscope and how quickly they appear to be dividing — it is not the same as stage, which describes how far the cancer has spread. The pathologist scores three features (how well the cancer forms duct-like tubules, how irregular the nuclei look, and how often cells are dividing) and adds them to give a grade of 1, 2 or 3. Grade 1 is well-differentiated and tends to grow more slowly; grade 3 is poorly differentiated and faster-growing. Grade is one of several factors — along with size, lymph node status and ER/PR/HER2 result — that the team weighs when deciding whether chemotherapy will add benefit.
Treatment combines local treatment with systemic treatment. Local treatment is surgery — either a breast-conserving lumpectomy or a mastectomy — usually with a sentinel lymph node biopsy to check the nodes, and radiation therapy after lumpectomy or for larger, node-positive tumours. Systemic treatment is chosen by the receptor subtype: hormone therapy for hormone-receptor-positive IDC, HER2-targeted therapy (anti-HER2 antibodies) for HER2-positive IDC, and chemotherapy where the grade, stage and subtype show it will help. At CION the exact combination and order are decided by a tumour board for your specific cancer, so you get treatment matched to your biology rather than a one-size-fits-all plan.
Early invasive ductal carcinoma is often treated with the goal of cure, and a large proportion of women are cured — especially when it is found early, is low grade and has not reached the lymph nodes. The outlook depends on three things together: the stage at diagnosis, the grade, and the receptor subtype. Advanced (metastatic) IDC, where the cancer has spread to distant organs, is generally not curable but is treatable; treatment can control it and extend good-quality life. Published survival figures are population averages from past patients — your own outlook depends on your specific tumour and how it responds to treatment, which is why an accurate, team-based plan matters so much.
Yes. CION offers a free first consultation for all cancer patients, including women newly diagnosed with invasive ductal carcinoma or seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy and receptor report, explains what "invasive ductal carcinoma" means for your treatment, confirms the grade, stage and subtype, and gives you a clear, tumor-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.